Mycoses invasives en France métropolitaine, PMSI 2001-2010 : incidence, létalité et tendances, pp.109-123, 2013. ,
The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study, Haematologica. août, vol.91, issue.8, pp.1068-75, 2006. ,
Prospective Surveillance for Invasive Fungal Infections in Hematopoietic Stem Cell Transplant Recipients, Overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database, vol.50, pp.1091-100, 2001. ,
, Épidémiologie de l'aspergillose invasive en France : résultat du réseau SAIF, pp.121-125, 2005.
Infections in Hematopoietic Cell Transplant Recipients: Results From the Organ Transplant Infection Project, a Multicenter, Prospective, Cohort Study, Open Forum Infect Dis, vol.4, issue.2, pp.1-7, 2017. ,
Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO), Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. juin, vol.20, issue.6, pp.872-80, 2014. ,
Candidémies en Île-de-France : données de l'Observatoire des levures, pp.125-133, 2002. ,
Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations, Blood Rev. mars, vol.31, issue.2, pp.17-29, 2017. ,
Candida and invasive mould diseases in non-neutropenic critically ill patients and patients with haematological cancer, Lancet Infect Dis. 31 juill, pp.1-13, 2017. ,
, Infections fongiques invasives : nouvelles données épidémiologiques et écologiques. Hématologie. 1 août, vol.14, pp.5-11, 2008.
,
, Association française des enseignants de parasitologie et mycologie. Parasitoses et mycosesElibrary France, 2016.
,
Infections en hématologie ,
Actualités sur l'épidémiologie et le diagnostic des infections fongiques invasives, Option/Bio. 1 janv, vol.28, issue.555, pp.13-18, 2017. ,
TUP1 sequences from Candida albicans and methods for screening agents for inhibiting virulence in Candida albicans using TUP1, 1997. ,
,
,
Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group, Clin Infect Dis Off Publ Infect Dis Soc Am. 15 juin, vol.46, issue.12, pp.1813-1834, 2008. ,
Aspergillose cérébrale en hématologie : apport de l'imagerie. À propos de deux cas, J Neuroradiol. 1 mars, vol.41, issue.1, p.28, 2014. ,
Hémopathies malignes : cancer du sang, causes et risques, Cancer Environnement, 2016. ,
, Société canadienne du cancer. Qu'est-ce que la leucémie aiguë myéloblastique ?
Risk Factors for Fungal Infection in Patients with Malignant Hematologic Disorders: Implications for Empirical Therapy and Prophylaxis, Clin Infect Dis. 1 avr, vol.18, issue.4, pp.525-557, 1994. ,
, Édition professionnelle du Manuel Merck, 2018.
Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study, Haematologica. avr, vol.95, issue.4, pp.644-50, 2010. ,
Complications of hematopoietic stem transplantation: Fungal infections, Hematol Oncol Stem Cell Ther. 13 juin, pp.239-283, 2017. ,
Defining Invasive Fungal Infection Risk in Hematological Malignancies: A New Tool for Clinical Practice, Mediterr J Hematol Infect Dis. 1 janv, vol.9, issue.1, pp.1-4, 2017. ,
,
guideline strategies for the use of antifungal agents in patients with hematological malignancies or hematopoietic stem cell transplantation recipients in Taiwan, J Microbiol Immunol Infect, vol.0, issue.0, pp.1-15, 2016. ,
Outcome of empirical or targeted antifungal therapy after antifungal prophylaxis in febrile neutropenia, Ann Hematol. mai, vol.95, issue.6, pp.1001-1010, 2016. ,
Triazole antifungals used for prophylaxis and treatment of invasive fungal disease in adult haematology patients: Trough serum concentrations in relation to outcome, Med Mycol, vol.54, issue.7, pp.691-699, 2016. ,
A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation, N Engl J Med. 26 mars, vol.326, issue.13, pp.845-51, 1992. ,
Fluconazole ARROW 100 mg gél, 2017. ,
,
Vfend 200 mg cp pelliculé, 2017. ,
,
Mycamine 100 mg poudre pour solution perfusion, 2017. ,
,
Itraconazole 100 mg gélule ,
,
ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients, Haematologica. 1 mars, vol.102, issue.3, pp.433-477, 2017. ,
Prophylaxie antibactérienne et antifongique chez les patients à haut risque en hématologie. Enquête de pratique et forum, Hematologie. 1 janv, vol.17, pp.3-15, 2011. ,
ECIL 6 meeting : Triazole Antifungal Therapeutic Drug Monitoring ,
Primary prophylaxis of invasive fungal diseases in allogeneic stem cell transplantation: revised recommendations from a consensus process by Gruppo Italiano Trapianto Midollo Osseo (GITMO), Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. août, vol.20, issue.8, pp.1080-1088, 2014. ,
Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO), Ann Hematol. 7 déc, pp.197-207, 2017. ,
Prophylaxie antifongique chez les patients d'hématologie en France : fréquences et choix de l'antifongique systémique en fonction du type d'hémopathie maligne (étude AFHEM), J Mycol Médicale. 1 sept, vol.25, issue.3, pp.225-231, 2015. ,
Quelles mesures pour maîtriser le risque infectieux chez les patients immunodéprimés ? Recommandations formalisées d'experts -Journal de Mycologie Médicale, pp.449-56, 2017. ,
A Quasi-Experimental Study Analyzing the Effectiveness of Portable High-Efficiency Particulate Absorption Filters in Preventing Infections in Hematology Patients during Construction, Turk J Hematol. mars, vol.33, issue.1, pp.41-48, 2016. ,
Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease, N Engl J Med. 25 janv, vol.356, issue.4, pp.335-382, 2007. ,
Evaluation of the Practice of Antifungal Prophylaxis Use in Patients With Newly Diagnosed Acute Myeloid Leukemia: Results From the SEIFEM 2010-B Registry, Clin Infect Dis. 1 déc, vol.55, issue.11, pp.1515-1536, 2012. ,
Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia, N Engl J Med. 25 janv, vol.356, issue.4, pp.348-59, 2007. ,
Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in highrisk patients with hematological malignancies, Int J Antimicrob Agents. 1 sept, vol.50, pp.384-392, 2017. ,
, Therapie, vol.62, issue.2, pp.115-137, 2010.
, , 2015.
Structural Characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei Bound to the Antifungal Drugs Posaconazole and Fluconazole, PLoS Negl Trop Dis. 6 avr, vol.4, issue.4, pp.1-15, 2010. ,
Noxafil 100 mg cp gastrorésis ,
,
Actualités des antifongiques systémiques, 2009. ,
, EMEA. Assessment report, 2014.
Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension, Antimicrob Agents Chemother. août, vol.56, issue.8, pp.4196-201, 2012. ,
Therapeutic Drug Monitoring of Posaconazole: an Update, Curr Fungal Infect Rep. 1 juin, vol.10, issue.2, pp.51-61, 2016. ,
Hot melt extruded amorphous solid dispersion of posaconazole with improved bioavailability: investigating drug-polymer miscibility with advanced characterisation, BioMed Res Int, vol.2014, pp.1-16, 2014. ,
Noxafil 300 mg sol diluer p perf, 2017. ,
,
Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD), J Pharm Sci. août, vol.99, issue.8, pp.3291-301, 2010. ,
Candidose invasive en réanimation, 2015. ,
Traitements des IFI et suivi thérapeutique pharmacologique -Documents ,
, , 2016.
,
Posaconazole: a broad-spectrum triazole antifungal, Lancet Infect Dis. déc, vol.5, issue.12, pp.775-85, 2005. ,
Posaconazole : un nouvel antifongique pour quelles indications ?, févr, vol.10, pp.42-51, 2008. ,
A Clinical Isolate of Candida albicans with Mutations in ERG11 (Encoding Sterol 14?-Demethylase) and ERG5 (Encoding C22 Desaturase) Is Cross Resistant to, Azoles and Amphotericin B. sept, vol.54, issue.9, pp.3578-83, 2010. ,
Effect of a high-fat meal on the pharmacokinetics of 300-milligram posaconazole in a solid oral tablet formulation, Antimicrob Agents Chemother, vol.59, issue.6, pp.3385-3394, 2015. ,
Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men, Antimicrob Agents Chemother. mars, vol.48, issue.3, pp.804-812, 2004. ,
Omeprazole significantly reduces posaconazole serum trough level, Clin Infect Dis Off Publ Infect Dis Soc Am. 15 mars, vol.48, issue.6, p.839, 2009. ,
Noxafil 100 mg Gastro-resistant Tablets -Summary of Product Characteristics, 2017. ,
,
Population Pharmacokinetics of Posaconazole Tablets and Monte Carlo Simulations To Determine whether All Patients Should Receive the Same Dose, Antimicrob Agents Chemother, vol.61, issue.11, pp.1-25, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01631527
Tissue penetration of antifungal agents, Clin Microbiol Rev. janv, vol.27, issue.1, pp.68-88, 2014. ,
Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil), Drug Metab Dispos Biol Fate Chem. févr, vol.32, issue.2, pp.267-71, 2004. ,
Pharmacocinétique (PK)/ Pharmacodynamie (PD) et place du suivi thérapeutique pharmacologique (STP) des antifongiques, vol.16, pp.329-368, 2010. ,
The role of azoles in the management of azole-resistant aspergillosis: from the bench to the bedside, Drug Resist Updat Rev Comment Antimicrob Anticancer Chemother. juill, vol.17, issue.3, pp.37-50, 2014. ,
Posaconazole Prophylaxis in Experimental Azole-Resistant Invasive Pulmonary Aspergillosis, Antimicrob Agents Chemother. mars, vol.59, issue.3, pp.1487-94, 2015. ,
, Posaconazole. Drugs. 1 août, vol.65, issue.11, pp.1553-67, 2005.
Increased inhibition of cytochrome P450 3A4 with the tablet formulation of posaconazole, Drug Metab Pharmacokinet, vol.31, issue.5, pp.389-93, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01376262
Effect of posaconazole on cyclosporine blood levels and dose adjustment in allogeneic blood and marrow transplant recipients, Antimicrob Agents Chemother. déc, vol.56, issue.12, pp.6422-6426, 2012. ,
, FDA : Noxafil, 2015.
Enjeux du suivi thérapeutique pharmacologique, Actual Pharm, vol.54, issue.549, pp.39-41, 2015. ,
Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations, J Antimicrob Chemother. 1 mars, vol.72, issue.suppl_1, pp.12-20, 2017. ,
Treatment of Invasive Aspergillosis with Posaconazole in Patients Who Are Refractory to or Intolerant of Conventional Therapy: An Externally Controlled Trial | Clinical Infectious Diseases | Oxford Academic, 2007. ,
Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology, J Antimicrob Chemother. 1 mai, vol.69, issue.5, pp.1162-76, 2014. ,
,
Posaconazole serum concentrations among cardiothoracic transplant recipients: factors impacting trough levels and correlation with clinical response to therapy, Antimicrob Agents Chemother. mars, vol.55, issue.3, pp.1308-1319, 2011. ,
Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease, J Antimicrob Chemother. mars, vol.71, issue.3, pp.718-744, 2016. ,
Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma, Clin Pharmacol Ther. juill, vol.88, issue.1, pp.115-124, 2010. ,
Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspective, Can J Infect Dis Med Microbiol, vol.25, issue.6, pp.327-370, 2014. ,
Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, Intern Med J. 1 déc, vol.44, issue.12b, pp.1364-88, 2014. ,
Therapeutic Drug Monitoring of Posaconazole in Allogeneic Hematopoietic Stem Cell Transplantation Patients Who Develop Gastrointestinal Graft-versus-Host Disease, Antimicrob Agents Chemother, vol.56, issue.10, pp.5247-52, 2012. ,
URL : https://hal.archives-ouvertes.fr/hal-00849695
Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration, Antimicrob Agents Chemother, vol.56, issue.11, pp.5503-5513, 2012. ,
Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis, Antimicrob Agents Chemother, vol.58, issue.11, pp.6767-72, 2014. ,
Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults, Antimicrob Agents Chemother. déc, vol.53, issue.12, pp.5224-5233, 2009. ,
Exposure-Response of Posaconazole Used for Prophylaxis Against Invasive Fungal Infections: Evaluating the Need to Adjust Doses Based on Drug Concentrations in Plasma -Jang -2010 -Clinical Pharmacology & Therapeutics -Wiley Online Library ,
,
Antifungal therapeutic drug monitoring: established and emerging indications, Antimicrob Agents Chemother. janv, vol.53, issue.1, pp.24-34, 2009. ,
Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults, Antimicrob Agents Chemother. sept, vol.47, issue.9, pp.2788-95, 2003. ,
A Reference Laboratory Experience of Clinically Achievable Voriconazole, Posaconazole, and Itraconazole Concentrations within the Bloodstream and Cerebral Spinal Fluid, Antimicrob Agents Chemother. 1 janv, vol.58, issue.1, pp.424-455, 2014. ,
Understanding Variability in Posaconazole Exposure Using an Integrated Population Pharmacokinetic Analysis, Antimicrob Agents Chemother. 11 janv, vol.58, issue.11, pp.6879-85, 2014. ,
Noxafil 40 mg/ml suspension buvable, 2017. ,
,
Nouvelle forme galénique du posaconazole ; Expérience d'un laboratoire hospitalier de pharmacologie, 2016. ,
Phase 1b Study of New Posaconazole Tablet for Prevention of Invasive Fungal Infections in High-Risk Patients with Neutropenia, Antimicrob Agents Chemother. 10 janv, vol.58, issue.10, pp.5758-65, 2014. ,
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers, Antimicrob Agents Chemother. mars, vol.53, issue.3, pp.958-66, 2009. ,
Effect of varying amounts of a liquid nutritional supplement on the pharmacokinetics of posaconazole in healthy volunteers, Antimicrob Agents Chemother, vol.53, issue.11, pp.4749-52, 2009. ,
Pharmacokinetics of Oral Posaconazole in Neutropenic Patients Receiving Chemotherapy for Acute Myelogenous Leukemia or Myelodysplastic Syndrome, Pharmacother J Hum Pharmacol Drug Ther, vol.28, issue.10, pp.1223-1255, 2008. ,
Comparison of posaconazole serum concentrations from haematological cancer patients on posaconazole tablet and oral suspension for treatment and prevention of invasive fungal infections, Mycoses. 6 janv, pp.226-259, 2016. ,
Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological Malignancies, Antimicrob Agents Chemother. 8 janv, vol.59, issue.8, pp.4424-4432, 2015. ,
Retrospective Comparison of Posaconazole Levels in Patients Taking the Delayed-Release Tablet versus the Oral Suspension, Antimicrob Agents Chemother. août, vol.59, issue.8, pp.4914-4922, 2015. ,
Evaluation of Serum Posaconazole Concentrations in Patients with Hematological Malignancies Receiving Posaconazole Suspension Compared to the Delayed-Release Tablet Formulation, Leuk Res Treat, pp.1-6, 2017. ,
Risk factors for subtherapeutic levels of posaconazole tablet, J Antimicrob Chemother, vol.72, issue.10, pp.2902-2907, 2017. ,
Safety study and therapeutic drug monitoring of the oral tablet formulation of posaconazole in patients with haematological malignancies, J Cancer Res Clin Oncol. 20 sept, vol.144, issue.1, pp.127-161, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01685802
Prevention of Invasive Aspergillus Fungal Infections with the Suspension and Delayed-Release Tablet Formulations of Posaconazole in Patients with Haematologic Malignancies, Sci Rep. 26 janv, vol.8, issue.1, pp.1-5, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01708516
Real-Life Assessment of the Safety and Effectiveness of the New Tablet and Intravenous Formulations of Posaconazole in the Prophylaxis of Invasive Fungal Infections via Analysis of 343 Courses, Antimicrob Agents Chemother. 8 janv, vol.61, issue.8, pp.1-12, 2017. ,
Posaconazole Tablet Formulation at 400 Milligrams Daily Achieves Desired Minimum Serum Concentrations in Adult Patients with a Hematologic Malignancy or Stem Cell Transplant, Antimicrob Agents Chemother, vol.60, issue.11, pp.6945-6952, 2016. ,
Serum posaconazole levels among haematological cancer patients taking extended release tablets is affected by body weight and diarrhoea: single centre retrospective analysis, Mycoses. juill, vol.58, issue.7, pp.432-438, 2015. ,
, Effect of Concomitant Medications Affecting Gastric pH and Motility on Posaconazole Tablet Pharmacokinetics, vol.58, pp.4020-4025, 2012.
Comparing Azole Plasma Trough Levels in Lung Transplant Recipients: Percentage of Therapeutic Levels and Intrapatient Variability, Ther Drug Monit. avr, vol.39, issue.2, pp.93-101, 2017. ,
Switching from posaconazole suspension to tablets increases serum drug levels in leukemia patients without clinically relevant hepatotoxicity, Antimicrob Agents Chemother, vol.58, issue.11, pp.6993-6998, 2014. ,
,
, Therapie. avr, vol.40, issue.2, pp.111-119, 1985.
Clinical hepatotoxicity associated with antifungal agents, Expert Opin Drug Saf. 1 févr, vol.16, issue.2, pp.149-65, 2017. ,
Posaconazole tablet formulation therapeutic drug monitoring and toxicity analysis, Poster presented at 54th Interscience conference on antimicrobial agents and chemotherapy, pp.5-9, 2014. ,
Cours Hématologie UE 2.9 S5 C4, 2017. ,
,
, Cancer Research Group. ECOG Performance Status
, , p.24, 2017.
, Annexe 2 Première différenciation d'une cellule souche totipotente (119)